This trial is evaluating whether Ruxolitinib will improve 1 primary outcome in patients with Lymphoma, T-Cell. Measurement will happen over the course of 1 year.
This trial requires 52 total participants across 1 different treatment group
This trial involves a single treatment. Ruxolitinib is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
"The rapid spread of lymphoma (or 'lymphomatosis') describes a subset of patients who have an increased risk of relapse and death after autologous stem cell transplantation (ASCT). Results from a recent clinical trial suggests that the presence of B-symptoms at ASCT should prompt a more intensive post-transplant follow-up." - Anonymous Online Contributor
"Lymphomas may present with symptoms similar to other illnesses. For example, B-cell lymphomas may resemble arthritis or fever. Other symptoms include swollen lymph nodes, unintentional weight loss, coughing up blood, feeling tired, hair loss, and skin changes. Symptoms usually improved after treatment." - Anonymous Online Contributor
"In summary, our meta-analysis suggests that RAI therapy is significantly superior to the standard care. We found no evidence for any superiority regarding OS compared to the current standard care. However, we could not observe any significant difference between the two groups regarding RR." - Anonymous Online Contributor
"Clinical trials can help patients get better care for their cancer. Physicians and nurses should counsel patients about possible risks and benefits of clinical trials. Families should great participate in the decision-making process by sharing their views." - Anonymous Online Contributor
"Ruxolitinib is well tolerated in patients with ALK+ large B-cell lymphomas. Common adverse reactions included muscle aches and weakness, headache, nausea, vomiting, and decreased appetite. Serious adverse events were uncommon, but included myelosuppression, elevated transaminases and diarrhea. Arrhythmia was infrequent, but may require close monitoring." - Anonymous Online Contributor
"Lymphoma, t-cell has been treated with chemotherapy and radiotherapy, but there is no effective cure for it. In the future, we need to develop new treatments for lymphomas, especially T-cells." - Anonymous Online Contributor
""Lymphoma, T-cell" is a breach of medical ethics because patients would not be able to know what type of cancer they have until they undergo diagnostic evaluation and treatment. show how medical professionals and ethicists work together to help patients make good decisions in the care of their own health." - Anonymous Online Contributor
"Of all people with an autoimmune disorder and no history of lymphoma, 7.7% will develop it at some point in their lifetimes. In contrast, only 1.3% will develop it within the first year of diagnosis.\n" - Anonymous Online Contributor
"Ruxolitinib has been well tolerated in this patient population. Although the safety of ruxolitinib in children has not yet been established, it appears to be efficacious in adults with relapsed or refractory indolent lymphomas." - Anonymous Online Contributor
"Researchers have made advances in the diagnosis of lymphoma. Type of lymphoma being diagnosed will vary depending upon the location of the lymphoma in the body. Some lymphomas are treated using chemotherapy alone, whereas others require combination therapy that includes radiation. Lymphoma tends to affect older men, although its exact cause remains unknown. Please see the table below for more information about the types of lymphoma and treatments available for each type of lymphoma." - Anonymous Online Contributor
"This data shows that ruxolitinib is effective against relapsed/refractory aggressive lymphomas including T-cell lymphomas such as primary mediastinal large B cell lymphoma (PMLBCL) and hairy cell leukemia. It should be used in combination with other agents or chemotherapy regimens when warranted." - Anonymous Online Contributor